CAMBRIDGE, Mass., May 22, 2023
/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq:
AKBA), a biopharmaceutical company with the purpose to better the
lives of people impacted by kidney disease, today announced that it
has received a formal notice from The Nasdaq Stock Market (Nasdaq)
stating that Akebia has regained compliance with the $1.00 per share minimum bid price requirement
pursuant to Nasdaq Listing Rule 5550(a)(2), and that Akebia is in
compliance with all applicable listing standards.
On May 9, 2023, Akebia was
notified by Nasdaq that Akebia had not regained compliance with the
big price requirement during the compliance period and Akebia's
securities were subject to delisting. Akebia filed an appeal and
was granted a hearing before the Nasdaq Hearings Panel. Since
Akebia has regained compliance, the hearing has been canceled.
Akebia's stock will continue to be listed and traded on The
Nasdaq Capital Market.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is
a fully integrated biopharmaceutical company with the purpose to
better the lives of people impacted by kidney disease. The Company
was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more
information, please visit our website at www.akebia.com, which does
not form a part of this release.
Akebia Therapeutics® is a registered trademark of
Akebia Therapeutics, Inc.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-301831338.html
SOURCE Akebia Therapeutics